Migraine: Current concepts and emerging therapies

Vascular Pharmacology

Volumn 43, Issue 3, 2005, Pages 176-187

  Arulmozhi, D K ^a,b   Veeranjaneyulu, A ^a   Bodhankar, S L ^b  

^a LUPIN LIMITED   (India)

^b BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

CGRP; Migraine; Serotonin; Triptan

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 METHYL 5 ISOTHIAZOLYL)UREA; 1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 3 (3 DIMETHYLAMINOPROPYL) 4 HYDROXY N [4 (4 PYRIDINYL)PHENYL]BENZAMIDE; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3 [3 (2 DIMETHYLAMINOETHYL) 1H INDOL 5 YL] N (4 METHOXYBENZYL)ACRYLAMIDE; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; ACETYLSALICYLIC ACID; ALMOTRIPTAN; ALNIDITAN; ANALGESIC AGENT; ANTIMIGRAINE AGENT; AS 19; AVITRIPTAN; BRL 54443; BUTALBITAL; CAFFEINE; DIHYDROERGOTAMINE; DIHYDROERGOTAMINE MESILATE; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; IMIGRAIN; ISOMETHEPTENE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; RIZATRIPTAN; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; HEADACHE; HUMAN; MIGRAINE; NAUSEA; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; VASODILATATION; VOMITING;

EID: 23844552236     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2005.07.001     Document Type: Article

References (102)

1. B. Ablad, and C. Dahlof Migraine and β-blockade: modulation of sympathetic neurotransmission Cephalalgia 6 1986 7 13
2. A.H. Ahn, and A.I. Basbaum Where do triptan act in the treatment of migraine? Pain 115 2005 1 4
3. U. Arulmani, A.M. VanDenBrink, C.M. Villalon, and P.R. Saxena Calcitonin gene-related peptide and its role in migraine pathophysiology Eur. J. Pharmacol. 500 2004 315 330
4. T. Bartsch, S. Akerman, and P.J. Goadsby The ORL-1 (NOP(1) receptor ligand nociceptin/orphanin FQ (/OFQ) inhibits neurogenic dural vasodilatation in the rat Neuropharmacology 43 2002 991 998
5. S.D. Brain, and A.D. Grat Vascular actions of calicitonin gene-related peptide and adrenomedullin Physiol. Rev. 84 2004 903 934
6. S.D. Brain, and T.J. Williams Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability Br. J. Pharmacol. 86 1985 855 860
7. M.F. Brin, D.M. Swope, C. O'Brien, S. Abbasi, and J.M. Pogoda Botox for migraine: double blind, placebo-controlled, region-specific evaluation Cephalalgia 20 2000 421 422
8. G.A. Bubenik, D.E. Blask, G.M. Brown, G.J. Maestroni, S.F. Pang, and R.J. Reiter Prospects and clinical utilization of melatonin Biol. Signals Recept. 7 1998 195 219
9. R. Burstein, M.F. Cutrer, and D. Yarnitsky The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine Brain 123 2000 1703 1709
10. M. Cui, S. Khanijou, J. Rubino, and K.R. Aoki Subcutaneous administration of botulinium toxin A reduces formalin-induced pain Pain 107 2004 125 133
11. F.M. Cutrer Antiepileptic drugs: how they work in headache Headache 41 Suppl 1 2001 S3 S10
12. 1D receptor antagonist Br. J. Pharmacol. 118 1996 85 92
13. 1D (BRL15572) receptor antagonists Eur. J. Pharmacol. 362 1998 69 72
14. P. De Vries, E.W. Willems, J.P. Heiligers, C.M. Villalon, and P.R. Saxena Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy Eur. J. Pharmacol. 375 1999 61 74
15. V. Dimitriadou, M.G. Buzzi, M.A. Moskowitz, and T.C. Theoharides Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells Neuroscience 44 1991 97 112
16. V. Dimitriadou, M.G. Buzzi, T.C. Theoharides, and M.A. Moskowitz Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation Neuroscience 48 1992 187 203
17. H. Doods, G. Hallermayer, D. Wu, M. Entzeroth, K. Rudolf, W. Engel, and W. Eberlein Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist Br. J. Pharmacol. 129 2000 420 423
18. A. Ducros, A. Joutel, K. Vahedi, M. Cecillon, A. Ferreira, E. Bernard, A. Verier, B. Echenne, A. Lopez de Munain, M.G. Bousser, and E. Tournier-Lasserve Mapping of a second locus for familial hemiplegic migraine to 1q21-q23 and evidence of further heterogeneity Ann. Neurol. 42 1997 885 890
19. P.L. Durham CGRP receptor antagonists - a fresh approach to migraine therapy? N. Engl. J. Med. 350 2004 1073 1075
20. P.L. Durham CGRP receptor antagonists: a new choice for acute treatment of migraine? Curr. Opin. Investig. Drugs 5 2004 731 735
21. L. Edvinsson Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of migraine Cephalalgia 24 2004 611 622
22. C. Ertsey, M. Hanto, G. Bozsik, and K. Tekes Circulating nociceptin levels during the cluster headache period Cephalalgia 24 2004 280 283
23. C. Ertsey, M. Hantos, G. Bozsik, and K. Tekes Plasma nociceptin levels are reduced in migraine without aura Cephalalgia 25 2005 261 266
24. W. Feindel, W. Penfield, and F. McNaughton The tentorial nerves and localization of intracranial pain in man Neurology 10 1960 555 563
25. M.D. Ferrari, J. Odnik, K.D. Bos, M.J.A. Malessey, and G.W. Bruyn Neuroexcitatory plasma amino acids are elevated in migraine Neurology 40 1990 1582 1583
26. J.R. Fozard The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraine? Arch. Int. Pharmacodyn. Ther. 329 1995 111 119
27. J.R. Fozard, and H.O. Kalkman 5-Hydroxytryptamine (5-HT) and the initiation of migriane: new perspectives Naunyn-Schmiedeberg's Arch. Pharmacol. 350 1994 225 229
28. B. Frei, M.C. Kim, and B.N. Ames Ubiquinol-10 is an effective lipid soluble antioxidant at physiological concentrations Proc. Natl. Acad. Sci. U. S. A. 87 1990 4879 4883
29. B.J. Freund, and M. Schwartz Treatment of chronic cervical-associated headache with botulinium toxin A: a pilot study Headache 40 2000 231 236
30. K. Gardner, M.M. Barmada, L.J. Ptacek, and E.P. Hoffman A new locus for hemiplegic migraine maps to chromosome 1q31 Neurology 49 1997 1231 1238
31. P.J. Goadsby Migraine: selecting treatments now and making requests for the future? Curr. Med. Res. Opin. 17 2001 S98 S99
32. P.J. Goadsby, and K.L. Hoskin The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study J. Anat. 190 1997 367 375
33. P.J. Goadsby, L. Edvinsson, and R. Ekman Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular systems Ann. Neurol. 23 1988 193 196
34. P.J. Goadsby, L. Edvinsson, and R. Ekman Release of vasocactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminal system Ann. Neurol. 23 1990 193 196
35. D.J. Goldstein, W.W. Offen, E.G. Klein, and L.A. Phebus Lanepitant, an NK-1 antagonist, in migraine Cephalalgia 19 1999 377
36. J.R. Graham, and H.G. Wolf Mechanism of migraine headache and action of ergotamine tartrate Arch. Neurol. Psychiatry 39 1938 737 763
37. R. Hering, and A. Kinitzky Sodium valproate in the prophylactic treatment of migraine. A double blind study versus placebo Cephalalgia 12 1992 81 84
38. J.P. Hieble Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics Pharm. Acta Helv. 74 2000 163 171
39. K.L. Hoskin, A.S. Zagami, and P.J. Goadsby Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat J. Anat. 194 1999 579 588
40. M. Hou, R. Uddman, J. Tajti, and L. Edvinsson Nociceptin iuumnoreactivity and receptor mRNA in the human trigeminal ganglion Brain Res. 964 2003 179 186
41. P.P. Humphrey, W. Feniuk, and M.J. Perren Anti-migraine drugs in development: advances in serotonin receptor pharmacology Headache 30 Suppl. 1 1990 12 16
42. International Headache Society International classification of headache disorders Cephalalgia 24 Sup.1 2004 1 160
43. M. Iovino, U. Feifel, C.L. Young, J.M. Wolters, and G. Wallenstein Safety, tolerability, and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in health volunteers Cephalalgia 24 2004 645 656
44. K.W. Johnson, L.A. Phebus, and M.L. Cohen Serotonin in migraine: theories, animal models and emerging therapies Prog. Drug Res. 51 1998 219 244
45. 2C receptor blockade? Life Sci. 54 1994 641 644
46. K. Kapoor, U. Arulmani, J.P. Heiligers, I.M. Garrelds, E.W. Willems, H. Doods, C.M. Villalon, and P.R. Saxena Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin induced carotid haemodynamic changes in anaesthetised pigs Br. J. Pharmacol. 140 2000 329 338
47. F.W. Kerr Atypical facial neuralgias: their mechanism as inferred from anatomic and physiologic data Mayo Clin. Proc. 36 1960 254 260
48. W.P. Koella CNS-related (side) effects of β-blockers with special reference mechanisms of action Eur. J. Clin. Pharmacol. 28 1985 55 63
49. K. Kovac, L. Tothfaulsi, F. Herman, and K. Magyar MAO activity, serotonin metabolism and aggregation of platelets from migraine patients. A preliminary study Pol. J. Pharmacol. Pharm. 40 1998 691 695
50. J.W. Lance Headache and face pain Med. J. Aust. 172 2000 450 455
51. J.W. Lance, G.A. Lambert, P.J. Goadsby, and J.W. Duckworth Brainstem influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraine Headache 23 1983 258 265
52. K.S. Lashley Patterns of cerebral integration indicated by the scotomas of migraine Arch. Neurol. 46 1941 331 339
53. J. Lashley, B. Larsen, and M. Lauritzen Related focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine Ann. Neurol. 9 1981 344 352
54. L.J. Launer, G.M. Terwindt, and M.D. Ferrari The prevalence and characteristics of migraine in a population-based cohort: the GEM study Neurology 53 1999 537 542
55. H. Lechner, E. Ott, F. Fazekas, and E. Pilger Evidence of enhance platelet aggregation and platelet sensitivity in migraine patients Cephalalgia 5 1985 89 91
56. R.B. Liption, and M.E. Bigal The epidemiology of migraine Am. J. Med. 118 2005 S3 S10
57. R.B. Lipton, M.E. Bigal, A.I. Scher, and W.F. Stewart The global burden of migraine J. Headaches Pain 4 2003 S3 S11
58. L. Magnus Nonepileptic use of gabapentine Epilepsia 40 1999 S66 S72
59. N. Mahant, P.D. Clouston, and I.T. Lorentz The current use of botulinium toxin J. Clin. Neurosci. 7 2000 389 394
60. P.R. Martin, D. Milech, and P.R. Nathan Towards a functional model of chronic headaches: investigation of antecedents and consequences Headache 33 1993 461 470
61. A. May, and P.J. Goadsby The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of neural influences on the cerebral circulation J. Cereb. Blood Flow Metab. 19 1999 115 127
62. A. May, S.L. Shepheard, M. Knorr, R. Effert, A. Wessing, R.J. Hargreaves, P.J. Goadsby, and H.C. Diener Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine Brain 121 1998 1231 1237
63. A. May, C. Buchel, R. Turner, and P.J. Goadsby Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation J. Cereb. Blood Flow Metab. 21 2001 1171 1176
64. M. Menken, T.L. Munsat, and J.F. Toole The global burden of disease study: implications for neurology Arch. Neurol. 57 2000 418 420
65. P. Michel, P. Henry, L. Letenneur, M. Jogeix, A. Corson, and J.F. Dartigues Diagnostic screen for assessment of the IHS criteria for migraine by general practitioners Cephalalgia 13 Suppl 12 1993 54 59
66. R.O. Milan-Guerrero, A.G. Pineda-Lucatero, T. Hernanadez-Benjamin, C.E. Tene, and M.F. Pacheco Naptha-methylhistamine. Safety and efficacy in migraine prophylaxis: phase I and phase II studies Headache 43 2003 389 394
67. P. Montagna The physiopathology of migraine: the contribution of genetics Neurol. Sci. 25 2004 S93 S96
68. T.D. Moran, F.A. Abdulla, and P.A. Smith Cellular neurophysiological actions of nociceptin/orphan FQ Peptides 21 2000 969 976
69. M.A. Moskowitz Basic mechanisms in vascular headache Neurol. Clin. 8 1990 801 815
70. M.A. Moskowitz Trigeminovascular system Cephalalgia 12 1992 127
71. M.A. Moskowitz Neurogenic inflammation in the pathophysiology and treatment of migraine Neurology 43 1993 S16 S20
72. M.A. Moskowitz, and F.M. Cutrer Sumatriptan: a receptor-targeted treatment for migraine Annu. Rev. Med. 44 1993 145 154
73. S. Moskowitz, K. Saito, and M.A. Moskowitz Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not in brain J. Neurosci. 7 1987 4129 4136
74. H. Ohhara, H. Kanaide, R. Yoshimura, M. Okada, and M. Nakamura A protective effect of coenzyme Q10 on ischemia and reperfusion of the isolated perfused rat heart J. Mol. Cell. 13 1981 65 74
75. J. Olesen, and R.B. Lipton Migraine classification and diagnosis. International Headache Society criteria Neurology 44 1994 S6 S10
76. J. Olesen, P. Tfelt-Hansen, L. Henriksen, and B. Larsen The common migraine attack may not be initiated by cerebral ischaemia Lancet 2 1981 438 440
77. J. Olesen, H. Diener, I.W. Husstedt, P.J. Goadsby, D. Hall, U. Meier, S. Pollentier, and L.M. Lesko Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine N. Engl. J. Med. 350 2004 1104 1110
78. R.A. Ophoff, R. van Eijk, L.A. Sandkuijl, G.M. Terwindt, C.P. Grubben, J. Haan, D. Lindhout, M.D. Ferrari, and R.R. Frants Genetic heterogeneity of familial hemiplegic migraine Genomics 22 1994 21 26
79. 2+ channel gene CACNL1A4 Cell 87 1996 543 552
80. R.A. Ophoff, A.M. van den Maagdenberg, K.I. Roon, M.D. Ferrari, and R.R. Frants The impact of pharmacogenetics for migraine Eur. J. Pharmacol. 9 2001 1 10
81. T. Paiva, A. Batista, and A. Martins The relationship between headaches and sleep disturbances Headache 35 1995 590 596
82. J.M. Pearce Migraine: a cerebral disorder Lancet 14 1984 86 89
83. M.F.P. Peres Melatonin, the pineal gland and their implications for headache disorders Cephalalgia 25 2005 403 411
84. K.A. Peterson, L.H. Lassen, S. Birk, L. Lesko, and J. Olesen BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation Clin. Pharmacol. Ther. 77 2005 202 213
85. K.A. Peterson, E. Nilsson, J. Olesen, and L. Edvinsson Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo Cephalalgia 25 2005 424 432
86. N.M. Ramadan, V. Skljarevski, L.A. Phebus, and K.W. Johnson 5-HT1F receptor agonists in acute migraine treatment: a hypothesis Cephalalagia 23 2003 776 785
87. B.K. Rasmussen, and J. Olesen Migraine with aura and migraine without aura: an epidemiological study Cephalalgia 12 1992 221 228
88. B.K. Rasmussen, R. Jensen, M. Schroll, and J. Olesen Interrelations between migraine and tension-type headache in the general population Arch. Neurol. 49 1992 914 918
89. T.D. Rozen, M.L. Oshinsky, C.A. Gebeline, K.C. Bradely, W.B. Young, and S.D. Silberstein Open label trial of coenzyme Q10 as a migraine preventive Cephalalgia 22 2002 137 141
90. K. Schmuck, C. Ullmer, H.O. Kalkman, A. Probst, and H. Lubbert Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur. J. Neurosci. 8 1996 959 967
91. J. Schoenen, and L.M. Jacquy Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial Neurology 50 1998 466 470
92. J. Schoenen, M. Lenaerts, and E. Bastings High dose riboflavin as a prophylactic treatment of migraine: results of an open label pilot study Cephalalgia 14 1994 328 329
93. W.J. Schulte-Mattler, T. Wieser, and S. Zierz Treatment of tension type headache with botulinium toxin: a pilot study Eur. J. Med. Res. 4 1999 183 186
94. S.D. Silberstein Migraine Lancet 363 2004 381 391
95. A. Slassi, M. Isaac, and J. Arora Novel serotonergic and non-serotonergic migraine headache therapies Expert Opin. Ther. Pat. 11 2001 625 649
96. S.D. Stilberstein, and M.M. Stilberstein New concepts in the pathogenesis of headache: Part II Pain Manage. 3 1990 334 342
97. 7 receptor involved in the pathogenesis and prophylactic treatment of migraine? Eur. J. Pharmacol. 439 2002 1 11
98. G.M. Terwindt, R.A. Ophoff, R. van Eijk, M.N. Vergouwe, J. Haan, R.R. Frants, L.A. Sandkuijl, M.D. Ferrari Dutch Migraine Genetics Research Group Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura Neurology 56 2001 1028 1032
99. P. Tfelt-Hansen, P.R. Saxena, C. Dahlof, J. Pascual, M. Lainez, P. Henry, H. Diener, J. Schoenen, M.D. Ferrari, and P.J. Goadsby Ergotamine in the acute treatment of migraine: a review and European consensus Brain 123 2000 9 18
100. R. Uddman, L. Edvinsn, R. Ekman, T. Kingman, and J. McCulloch Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin-gene-related peptide: trigeminal orgin and co-existence with substance P Neurosci. Lett. 62 1985 131 136
101. 1B/1D receptors and α-adrenoceptors Br. J. Pharmacol. 1265 1999 385 394
102. E.W. Willems, L.F. Valdivia, C.M. Villalon, and P.R. Saxena Possible role of α-adrenoceptor subtypes in acute migraine therapy Cephalalgia 23 2003 245 257